NIH State-of-the-Science Conference:
Diagnosis and Management of
Ductal Carcinoma in Situ (DCIS)
September 22-24, 2009
Bethesda, Maryland
Conference Home
Final Statement | PDF
Program & Abstracts | PDF
Archived Videocast Day 1 | 2 | 3
Evidence Report
Planning Committee | Panel
Sponsors
Agenda
Documents in PDF format require the Adobe Acrobat Reader®.
If you experience problems with PDF documents, please download
the latest version of the Reader®.
National Cancer Institute
Office of Medical Applications of Research
of the National Institutes of Health
Office of Research on Women's Health
Agency for Healthcare Research and Quality
Centers for Disease Control and Prevention
U.S. Food and Drug Administration
Tuesday, September 22, 2009
| 8:30 a.m. | Opening Remarks
Worta McCaskill-Stevens, M.D., M.S. |
| 8:40 a.m. | Charge to the Panel Jennifer Miller Croswell, M.D. Acting Director Office of Medical Applications of Research Office of the Director National Institutes of Health |
| 8:50 a.m. | Conference Overview and Panel Activities Carmen J. Allegra, M.D. Panel and Conference Chairperson Chief, Hematology and Oncology Associate Director for Clinical and Translational Research Shands Cancer Center University of Florida |
| 9:00 a.m. | Terminology, Natural History, and Taxonomy of DCIS D. Craig Allred, M.D. Director, Breast Pathology Professor, Pathology and Immunology Washington University School of Medicine |
| I. | What are the incidence and prevalence of DCIS and its specific pathologic subtypes, and how are incidence and prevalence influenced by mode of detection, population characteristics, and other risk factors? |
| 9:20 a.m. | Epidemiology of DCIS |
| 9:40 a.m. | Mode of Detection & Secular Time |
| 10:00 a.m. | Evidence-Based Practice Center Presentation I: The Incidence and Prevalence of DCIS and
the Influence of Mode of Detection, Population Characteristics, and Other Risk Factors Beth A. Virnig, Ph.D., M.P.H. Professor Division of Health Policy and Management University of Minnesota School of Public Health |
| 10:20 a.m. | Discussion |
| 11:00 a.m. | Sentinel Lymph Node Biopsy and Management of the Axilla Thomas B. Julian, M.D., F.A.C.S. Associate Director, Breast Care Center West Penn Allegheny Health System Associate Professor, Human Oncology Drexel University College of Medicine Senior Director, Medical Affairs National Surgical Adjuvant Breast and Bowel Project (NSABP) |
| 11:20 a.m. | MRI in Patients Diagnosed With DCIS Constance D. Lehman, M.D., Ph.D. Vice Chair and Professor of Radiology Section Head, Breast Imaging University of Washington School of Medicine Director of Medical Imaging Seattle Cancer Care Alliance |
| 11:40 a.m. | Evidence-Based Practice Center Presentation II: The Impact of Magnetic Resonance Imaging and Sentinel Lymph Node Biopsy on Important Outcomes in Patients Diagnosed with DCIS Todd M. Tuttle, M.D. Professor Department of Surgery University of Minnesota Medical School |
| 12:00 p.m. | Discussion |
| 12:30 p.m. | Lunch Panel Executive Session |
| II. | How does the use of MRI or sentinel lymph node biopsy impact important outcomes in patients diagnosed with DCIS? |
11:00 a.m. |
|
| 11:20 a.m. | MRI in Patients Diagnosed With DCIS Constance D. Lehman, M.D., Ph.D. Vice Chair and Professor of Radiology Section Head, Breast Imaging University of Washington School of Medicine Director of Medical Imaging Seattle Cancer Care Alliance |
| 11:40 a.m. | Evidence-Based Practice Center Presentation II: The Impact of Magnetic Resonance Imaging and Sentinel Lymph Node Biopsy on Important Outcomes in Patients Diagnosed with DCIS Todd M. Tuttle, M.D. Professor Department of Surgery University of Minnesota Medical School |
| 12:00 p.m. | Discussion |
| 12:30 p.m. | Lunch Panel Executive Session |
| III. | How do local control and systemic outcomes vary in DCIS based on tumor and patient characteristics? |
| 1:30 p.m. | Local Control of DCIS Based on Tumor and Patient Characteristics: |
| 1:50 p.m. | Local and Systemic Outcomes in DCIS Based on Tumor and Patient Characteristics: The Pathologist’s Perspective Stuart Schnitt, M.D. Director, Division of Anatomic Pathology Beth Israel Deaconess Medical Center Professor of Pathology Harvard Medical School |
| 2:10 p.m. | Meta-Analysis of DCIS Trials: Outcomes From the Early Breast Cancer Trialists’ Collaborative Group Sarah C. Darby, Ph.D. Professor of Medical Statistics Clinical Trials Service Unit University of Oxford |
| 2:30 p.m. | Local and Systemic Outcomes in DCIS Based on Tumor and Patient Characteristics: The Radiation Oncologist’s Perspective Nina Bijker, M.D., Ph.D. Department of Radiation Oncology Academic Medical Center University of Amsterdam |
| 2:50 p.m. | DCIS Outcomes in Breast Cancer Chemoprevention Trials Victor G. Vogel III, M.D., M.H.S. National Vice President, Research American Cancer Society |
| 3:10 p.m. | Evidence-Based Practice Center Presentation III: Tumor and Patient Characteristics and Associated Outcomes in DCIS Tatyana A. Shamliyan, M.D., M.S. Research Associate Division of Health Policy and Management University of Minnesota School of Public Health |
| 3:30 p.m. | Discussion |
| 4:30 p.m. | The Impact of Radiation Therapy on DCIS Outcomes Lawrence J. Solin, M.D., F.A.C.R. Chairman Department of Radiation Oncology Albert Einstein Medical Center |
| 4:50 p.m. | The Impact of Surgery on DCIS Outcomes: The Van Nuys Prognostic Index Melvin J. Silverstein, M.D. Professor of Surgery University of Southern California Heck School of Medicine Director, Hoag Breast Program Hoag Memorial Hospital Presbyterian |
| 5:10 p.m. | Discussion |
| 5:30 p.m. | Adjournment |
Wednesday, September 23, 2009
| IV. | In patients with DCIS, what is the impact of surgery, radiation, and systemic treatment on outcomes? |
| 8:30 a.m. | The Impact of Surgery on DCIS Outcomes: The Use of Mastectomy |
| 8:50 a.m. | The Impact of Systemic Therapy on DCIS Outcomes Sandra M. Swain, M.D. Medical Director Washington Cancer Institute Washington Hospital Center Professor of Medicine Georgetown University |
| 9:10 a.m. | Communications Between Patients and Providers and Informed Decision-Making Joann G. Elmore M.D., M.P.H. |
| 9:30 a.m. | Evidence-Based Practice Center Presentation IV: The Impact of Surgery, Radiation, and
Systemic Treatment on Outcomes in Patients with Ductal Carcinoma in Situ Robert L. Kane, M.D. Director, Minnesota Evidence-based Practice Center Professor Minnesota Chair in Long-term Care and Aging University of Minnesota School of Public Health |
| 9:50 a.m. | Discussion |
| IV. | What are the most critical research questions for the diagnosis and management of DCIS? |
| 10:50 a.m. | Molecular Markers for the Diagnosis and Management of DCIS |
| 11:10 a.m. | Imaging for the Diagnosis and Management of DCIS Carl J. D'Orsi, M.D., F.A.C.R. Professor of Radiology, Hematology, and Oncology Director, Division of Breast Imaging Emory University Hospital |
| 11:30 a.m. | Quality of Life Issues and Outcomes Research in DCIS Patricia A. Ganz, M.D. Professor of Health Services and Medicine School of Public Health and David Geffen School of Medicine Director Division of Cancer Prevention and Control Research Jonsson Comprehensive Cancer Center University of California, Los Angeles |
| 11:50 a.m. | Discussion |
| 12:20 p.m. | Adjournment |
Thursday, September 24, 2009
| 9:00 a.m. | Presentation of the Draft Consensus Statement |
| 9:30 a.m. | Public Discussion |
| 11:00 a.m. | Panel Meets in Executive Session Adjournment |
| 2:00 p.m. | Press Telebriefing |
To top
Contact Consensus Program |
Privacy Notice |
Disclaimer |
Accessibility |
Contact NIH
